SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study.

Tina KoClaire DendleIan J WoolleyEric MorandAnna Antony

Published in: Human vaccines & immunotherapeutics (2021)

SARS-COV-2 vaccine hesitancy is prevalent amongst RMD patients and associated with concerns regarding vaccine safety, efficacy, side effects and RMD flare. Clinician recommendation, vaccine choice and communications targeting patient concerns could facilitate vaccine acceptance.Significance and Innovations Vaccine hesitancy is prevalent in RMD patientsVaccine acceptance is associated with beliefs regarding vaccine safety and efficacy and concerns regarding RMD flare and vaccine-associated side effectsVaccine choice and clinician recommendation have the potential to improve vaccine acceptance in patients who are hesitant.

Keyphrases

sars cov
end stage renal disease
newly diagnosed
ejection fraction
physical activity
case report
respiratory syndrome coronavirus
climate change
cancer therapy